Follow the people · Insider
Jennifer Champoux
Jennifer Champoux files insider transactions with the SEC as a chief operating officer of Monte Rosa Therapeutics (GLUE). We hold 6 disclosed purchases and sales filed since 5 June 2024, 3 of them in the last 90 days.
- Files forGLUE
- Disclosed buys and sells6 in all, 3 in the last 90 days
- Last disclosure16 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 June 2024 — 15 July 2026Chief Operating Officer · Monte Rosa Therapeutics (GLUE)24 Form 4 lines · source: SEC Form 4
Everything they disclosed
24 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 4,351 shares of Monte Rosa TherapeuticsSEC Form 416 July 2026Common Stock · traded 15 July 2026 · filed 16 July 2026
- ▼ sold on the open market 4,351 shares of Monte Rosa TherapeuticsSEC Form 416 July 2026Common Stock · traded 15 July 2026 · filed 16 July 2026
- exercised options over 4,351 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 416 July 2026Stock Option (Right to Buy) · traded 15 July 2026 · filed 16 July 2026
- exercised options over 2,175 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- ▼ sold on the open market 2,175 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 2,175 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 23 June 2026 · filed 25 June 2026
- exercised options over 2,176 shares of Monte Rosa TherapeuticsSEC Form 418 June 2026Common Stock · traded 17 June 2026 · filed 18 June 2026
- ▼ sold on the open market 2,176 shares of Monte Rosa TherapeuticsSEC Form 418 June 2026Common Stock · traded 17 June 2026 · filed 18 June 2026
- exercised options over 2,176 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 418 June 2026Stock Option (Right to Buy) · traded 17 June 2026 · filed 18 June 2026
- exercised options over 2,175 shares of Monte Rosa TherapeuticsSEC Form 428 May 2026Common Stock · traded 27 May 2026 · filed 28 May 2026
- ▼ sold on the open market 2,175 shares of Monte Rosa TherapeuticsSEC Form 428 May 2026Common Stock · traded 27 May 2026 · filed 28 May 2026
- exercised options over 2,175 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 428 May 2026Stock Option (Right to Buy) · traded 27 May 2026 · filed 28 May 2026
- exercised options over 2,176 shares of Monte Rosa TherapeuticsSEC Form 426 May 2026Common Stock · traded 22 May 2026 · filed 26 May 2026
- ▼ sold on the open market 2,176 shares of Monte Rosa TherapeuticsSEC Form 426 May 2026Common Stock · traded 22 May 2026 · filed 26 May 2026
- exercised options over 2,176 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 426 May 2026Stock Option (Right to Buy) · traded 22 May 2026 · filed 26 May 2026
- was granted 35,000 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 2,629 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 5 January 2026 · filed 5 January 2026
- was granted 158,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 5 January 2026
- was granted 158,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 5 January 2026
- was granted 35,000 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 2,629 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 5 January 2026 · filed 5 January 2026
- was granted 135,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 46 January 2025Stock Option (Right to Buy) · traded 2 January 2025 · filed 6 January 2025
- was granted 30,000 shares of Monte Rosa TherapeuticsSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 40,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 June 2024Stock Option (Right to Buy) · traded 3 June 2024 · filed 5 June 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.